Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02495844
Previous Study | Return to List | Next Study

A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02495844
Recruitment Status : Completed
First Posted : July 13, 2015
Results First Posted : February 5, 2019
Last Update Posted : February 5, 2019
Sponsor:
Collaborator:
PRA Health Sciences
Information provided by (Responsible Party):
UCB Pharma ( UCB Biopharma S.P.R.L. )

Brief Summary:
This study is to assess the efficacy, safety, and tolerability of the investigational drug UCB0942in adult subjects with drug-resistant focal epilepsy across multiple centers in Europe.

Condition or disease Intervention/treatment Phase
Highly Drug-resistant Focal Epilepsy Drug: UCB0942 Drug: Placebo Phase 2

Detailed Description:
The study will include a Screening Visit, a Prospective Outpatient Baseline Period (2 to 3 weeks), an Inpatient Period (3 weeks), an Outpatient Period (8 weeks of treatment and 2 weeks of taper), and a Safety Follow-Up Period (4 weeks). The total study duration after screening will be 19 to 20 weeks. Approximately 6 months after the last visit subjects will be asked to return for an additional visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy.
Study Start Date : July 2015
Actual Primary Completion Date : February 2017
Actual Study Completion Date : July 2017


Arm Intervention/treatment
Experimental: UCB0942
UCB0942/UCB0942
Drug: UCB0942
Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use

Drug: UCB0942
Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use

Placebo Comparator: Placebo
Placebo/UCB0942 (after 2-week inpatient period, placebo subjects will receive the experimental medicine, UCB0942).
Drug: UCB0942
Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use

Drug: Placebo
Pharmaceutical form: Film-coated tablet Route of administration: Oral use




Primary Outcome Measures :
  1. 75 % Responder Rate During the 2-week Inpatient Period [ Time Frame: During the 2-week Inpatient Period ]
    The 75% responder rate is defined as the percentage of subjects with a 75 % or greater reduction in focal seizure frequency during the 2-week Inpatient Period compared with the Baseline Period.


Secondary Outcome Measures :
  1. Median Percent Change in Weekly Focal Seizure Frequency During the 2-week Inpatient Period [ Time Frame: During the 2-week Inpatient Period ]
    A negative value in median percent change reflects a reduction from Baseline.

  2. Median Percent Change in Weekly Focal Seizure Frequency During the Outpatient Maintenance Period [ Time Frame: During the Outpatient Maintenance Period (8 weeks) ]
    A negative value in median percent change reflects a reduction from Baseline.

  3. Median Percent Change in Weekly Focal Seizure Frequency During the On-UCB0942 Overall Period [ Time Frame: During the On-UCB0942 Overall Period (approximately 11 weeks) ]
    A negative value in median percent change reflects a reduction from Baseline.

  4. Seizure-free Rate (All Seizures) During the 2-week Inpatient Period [ Time Frame: During the 2-week Inpatient Period ]
    Seizure-free rate is reported as the percentage of seizure-free participants during the 2-week Inpatient Period.

  5. Seizure-free Rate (All Seizures) During the Last 4 Weeks of the Outpatient Maintenance Period [ Time Frame: During the last 4 weeks of the Outpatient Maintenance Period ]
    Seizure-free rate is reported as the percentage of seizure-free participants during the last 4 weeks of the Outpatient Maintenance Period.

  6. Seizure-free Rate (All Seizures) During the On-UCB0942 Overall Period [ Time Frame: During the On-UCB0942 Overall Period (approximately 11 weeks) ]
    Seizure-free rate is reported as the percentage of seizure-free participants during the On-UCB0942 Overall Period.

  7. 75 % Responder Rate During the Last 4 Weeks of the Outpatient Maintenance Period [ Time Frame: During the last 4 weeks of the Outpatient Maintenance Period ]
    The 75 % responder rate is defined as the percentage of subjects who achieve a 75 % or greater reduction in focal seizure frequency.

  8. 75 % Responder Rate During the On-UCB0942 Overall Period [ Time Frame: During the On-UCB0942 Overall Period (approximately 11 weeks) ]
    The 75 % responder rate is defined as the percentage of subjects who achieve a 75 % or greater reduction in focal seizure frequency.

  9. Percentage of Seizure Free Days (All Seizures) During the 2-week Inpatient Period [ Time Frame: During the 2-week Inpatient Period ]
    For the active group, the 2-week Inpatient Period refers to the last 2 weeks of the Inpatient Period, while for the Placebo group, it refers to the first 2 weeks of the Inpatient Period.

  10. Percentage of Seizure-free Days (All Seizures) During the Outpatient Maintenance Period [ Time Frame: During the Outpatient Maintenance Period (8 weeks) ]
  11. Number of Patients Reporting at Least One Serious Adverse Event (SAE) During the Course of the Study [ Time Frame: All study duration (approximately 19 to 20 weeks) ]
    Number of subjects experiencing at least one serious adverse event (reported by the subject and/or caregiver or observed by the Investigator or inpatient staff).

  12. Number of Subject Withdrawals Due to Adverse Events (AEs) During the Course of the Study [ Time Frame: All study duration (approximately 19 to 20 weeks) ]
    Number of subjects who withdrew from the study due adverse event (reported by the subject and/or caregiver or observed by the Investigator or inpatient staff).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is an adult (18 years of age or more)
  • Subject is able to understand the study and the ICF as assessed by the Investigator. Subjects with known mental retardation (defined as IQ below 70) are not eligible to participate. Subject and/or caregiver is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule, and the medication intake scheme as instructed according to the judgment of the Investigator
  • Subject fulfills ILAE (1989) criteria for focal epilepsy; clinical semiology should be described and fulfill criteria for focal seizures; there will have been an electroencephalogram (EEG) reading compatible with focal epilepsy in the last 5 years; the subject has no seizures that are not focal by the new ILAE criteria; a brain MRI (magnetic resonance imaging) or head CT (computed tomography) to be performed before randomization, if no such scan was performed in the last 5 years, and a report is available. If a scan was performed within the last 5 years but the epilepsy has not been stable since the last scan, a new scan should be obtained
  • Subject has failed to achieve seizure control with ≥4 appropriately chosen Antiepileptic Drug (AED) regimens of adequate dose and duration, including the current treatment, as documented in medical records and per Investigator assessment of patient report
  • Subject is currently treated with a stable dose of at least 1 AED for the 4 weeks prior to the Screening Visit (Visit 1) and throughout the duration of the Treatment Period with or without additional concurrent vagus nerve stimulation (VNS) or other neurostimulation treatments. The VNS must have been in place for at least 12 months with constant settings for at least 3 months and the battery life of unit anticipated to extend for the duration of study prior to the Screening Visit and throughout the duration of the study
  • During the 4 weeks prior to Screening (Historical Baseline Period), subject must report to have had an average of at least 4 spontaneous and observable focal seizures per week ("focal seizures" refers to partial-onset seizures of type IA1, IB, and IC, but does not include type IA2, IA3, or IA4 seizures), and cannot have had any seizure-free period longer than 3 days (based on Investigator assessment of subject report and seizure diaries if available). The cut-off seizure frequency (4 seizures per week) and maximum seizure-free interval (3 days) must be maintained during the 2-week Prospective Outpatient Baseline Period
  • Female subjects of nonchildbearing potential (premenarcheal, postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, and complete hysterectomy) are eligible. Female subjects of childbearing potential are eligible if they use medically accepted contraceptive methods. Oral or depot contraceptive treatment with at least ethinylestradiol 30 μg per intake used with an additional barrier contraception method, monogamous relationship with vasectomized or female partner, or double-barrier contraception are acceptable methods. The subject must understand the consequences and potential risks of inadequately protected sexual activity, be educated about and understand the proper use of contraceptive methods, and undertake to inform the Investigator of any potential change in status. Abstinence will be considered as an acceptable method of contraception if the Investigator can document that the subject agrees to be compliant when it is in line with the preferred and usual lifestyle of the subject
  • Male subjects confirm that during the study period and for a period of 3 months after the final dose, when having sexual intercourse with a woman of childbearing potential, he will use a barrier contraceptive (eg, condom) and that the respective partner will use an additional contraceptive method

Exclusion Criteria:

  • Subject has participated in another study of an investigational medication (or medical device) within the last 30 days or is currently participating in another study of an investigational medication (or a medical device)
  • Subject has a known hypersensitivity to any components of UCB0942 formulation or to similar drugs (LEV, BRV, or benzodiazepines), or a history of drug or other allergy that, in the opinion of the Investigator or UCB Study Physician, contraindicates her/his participation
  • Subject has a current or past psychiatric condition that, in the opinion of the Investigator, could compromise his/her safety or ability to participate in this study including a history of schizophrenia, schizoaffective disorder, bipolar disorder, or severe unipolar depression. The presence of potential psychiatric exclusion criteria will be determined based on screening with the BPRS plus the Mini International Neuropsychiatric Interview (MINI)
  • Subject has taken other (non-AED) prescription, nonprescription, dietary (eg, grapefruit or passion fruit), or herbal products that are potent inducers or inhibitors of the CYP3A4 pathway for 2 weeks (or 5 half-lives, whichever is longer) prior to the Baseline Visit
  • Subject is currently treated with carbamazepine, phenytoin, primidone, or phenobarbital or any other drug known to induce CYP3A4 liver enzymes; Subject is taking tiagabine, felbamate, or vigabatrin; Subject is taking benzodiazepines, zolpidem, zaleplon, or zopiclone >3 times per week for any indication
  • Subject has a clinically significant abnormality on echocardiography at Screening or a history of rheumatic heart disease or other known valvular abnormalities
  • Subjects with a history of hypersensitivity reactions or autoimmune disease
  • Female subject who is pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02495844


Locations
Show Show 18 study locations
Sponsors and Collaborators
UCB Biopharma S.P.R.L.
PRA Health Sciences
Investigators
Layout table for investigator information
Study Director: UCB Cares +1 844 599 2273 (UCB)
  Study Documents (Full-Text)

Documents provided by UCB Pharma ( UCB Biopharma S.P.R.L. ):
Study Protocol  [PDF] October 10, 2016
Statistical Analysis Plan  [PDF] October 7, 2016


Layout table for additonal information
Responsible Party: UCB Biopharma S.P.R.L.
ClinicalTrials.gov Identifier: NCT02495844    
Other Study ID Numbers: EP0069
2014-003330-12 ( EudraCT Number )
First Posted: July 13, 2015    Key Record Dates
Results First Posted: February 5, 2019
Last Update Posted: February 5, 2019
Last Verified: February 2019
Keywords provided by UCB Pharma ( UCB Biopharma S.P.R.L. ):
UCB0942
Treatment-resistant focal epilepsy
Partial seizures
Seizure therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases